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Abstract. There is an urgent need for rapid methods to develop vaccines in response to emerging viral patho-
gens. Whole inactivated virus (WIV) vaccines represent an ideal strategy for this purpose; however, a universal
method for producing safe and immunogenic inactivated vaccines is lacking. Conventional pathogen inactivation
methods such as formalin, heat, ultraviolet light, and gamma rays cause structural alterations in vaccines that
lead to reduced neutralizing antibody specificity, and in some cases, disastrous T helper type 2-mediated
immune pathology. We have evaluated the potential of a visible ultrashort pulsed (USP) laser method to gen-
erate safe and immunogenic WIV vaccines without adjuvants. Specifically, we demonstrate that vaccination of
mice with laser-inactivated H1N1 influenza virus at about a 10-fold lower dose than that required using conven-
tional formalin-inactivated influenza vaccines results in protection against lethal H1N1 challenge in mice. The
virus, inactivated by the USP laser irradiation, has been shown to retain its surface protein structure through
hemagglutination assay. Unlike conventional inactivation methods, laser treatment did not generate carbonyl
groups in protein, thereby reducing the risk of adverse vaccine-elicited T helper type 2 responses. Therefore,
USP laser treatment is an attractive potential strategy to generate WIV vaccines with greater potency and safety
than vaccines produced by current inactivation techniques. © The Authors. Published by SPIE under a Creative Commons
Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including
its DOI. [DOI: 10.1117/1.JBO.20.5.051008]
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1 Introduction
Emerging viral pathogens are a constant and prominent threat to
human health worldwide, as evidenced by the recent outbreak of
severe acute respiratory syndrome (SARS), Middle East respi-
ratory syndrome (MERS) coronaviruses, and novel influenza
strains with pandemic potential. In addition, there is a persistent
risk of engineered viruses derived from bioterrorism. The most
logical and cost-effective strategy to protect the human popula-
tion from these emerging viral diseases is through immuniza-
tion. Thus, there is a dire need for rapid methods to develop
vaccines in response to new viral pathogens.
Whole inactivated virus (WIV) vaccines represent an ideal
strategy for this purpose. In contrast to subunit or recombinant
vector vaccines, WIV vaccines circumvent the need to identify
relevant antigens and can be quickly produced from purified
virus using chemical or physical inactivation methods. WIV
vaccines contain many of the immunogenic epitopes and immu-
nostimulatory components (such as toll-like receptor ligands)
that are needed for an effective virus-specific immune response.
Unfortunately, a general method for producing safe and
immunogenic WIV vaccines is lacking. Formalin, an alkylating
agent, is one of the most extensively used methods for virus
inactivation in the manufacture of vaccines.1,2 However, for-
malin treatment has several crucial limitations: (1) it causes
structural damage to B-cell epitopes, which reduces the speci-
ficity of antibody responses elicited by the vaccine;3 (2) it gen-
erates carbonyl groups in proteins,4 a form of oxidative damage
that induces harmful and undesirable T helper type 2 (Th2) -
biased immune responses;5 and (3) it adds unnecessary cost and
public concern by introducing a carcinogen into the vaccine.
These limitations can be seen in the failure of formalin-inacti-
vated respiratory syncytial virus and measles vaccines, which
caused disastrous worsening of the disease upon natural infec-
tion.6–9 Alternative methods for virus inactivation, including
other alkylating agents, heat, ultraviolet (UV) light, and gamma
radiation, all suffer from various combinations of the abovemen-
tioned limitations.10–13
Recently, a novel method for pathogen inactivation using vis-
ible ultrashort pulsed (USP) lasers has been reported (Ref. 14).
Visible USP laser treatment inactivates viruses through a physi-
cal mechanism: the impulsive stimulated Raman scattering
(ISRS) process.15,16 There are several theoretical reasons why
USP lasers would be advantageous over other methods for*Address all correspondence to: Kong-Thon Tsen, E-mail: tsen@asu.edu;
Chien-Fu Hung, E-mail: chung2@jhmi.edu
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WIV vaccine production. Visible light (in the wavelength range
of 400 to 700 nm) lacks the photon energy to disrupt covalent
bonds in biological macromolecules such as viruses; therefore,
USP laser irradiation should not generate Th2 response-induc-
ing carbonyl groups in proteins. In the absence of chromo-
phores, visible light shows negligible intrinsic absorption by
proteins and nucleic acids; thus, USP laser irradiation should
not denature structural B-cell epitopes through heating. In addi-
tion, USP laser irradiation does not induce protein–nucleic
acid crosslinking; hence, the TLR-stimulating capacity of viral
nucleic acids should be preserved. Furthermore, the USP laser
method does not involve introducing any potentially toxic or
carcinogenic chemicals during treatment and would alleviate
public concerns in those regard. These rationales make the
USP laser treatment an attractive potential method to generate
safe and effective WIV vaccines.
In this paper, we demonstrate that immunization of mice with
the USP laser-inactivated whole inactivated H1N1 influenza
virus at about a 10-fold lower dose than that required by conven-
tionally formalin-inactivated H1N1 vaccine results in protection
against lethal-dose H1N1 influenza challenge. Splenocytes
extracted from mice vaccinated with the USP laser-inactivated
virus showed an enhanced influenza-specific cytotoxic T-cell
(CTL) response compared with those from unvaccinated mice.
In addition, we employed a neutralization assay to confirm the
presence of neutralizing antibodies. We demonstrate through
hemagglutination assay that the USP laser irradiation has no
effect on the surface protein structure of the virus. Furthermore,
we have evaluated the effects of USP laser–treatment on a model
protein—bovine serum albumin (BSA). We have found that, in
contrast to conventional pathogen inactivation methods, the
USP laser treatment did not generate Th2 response-inducing car-
bonyl groups in BSA protein. Therefore, USP laser treatment is
a novel and an attractive potential strategy to generate WIV vac-
cines with greater potency and safety than vaccines produced by
current inactivation techniques.
2 Materials and Methods
2.1 Mice
Female BALB/c mice (8 weeks old) were obtained from the
National Cancer Institute (Bethesda, Maryland). The mice
were kept in a pathogen-free environment at Johns Hopkins
University (Baltimore, Maryland).
2.2 Cells
Madin-Darby canine Kidney (MDCK) cells, obtained from
ATCC (Manassas, Virginia), were used for all in vitro assays.
Cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) with L-glutamine and 10% FBS at 37°C with 5% CO2.
2.3 Virus
The strain of virus used in this study was A/PR/8/34 (H1N1)
from ATCC (Manassas, Virginia). The virus was first grown
in MDCK host cells. After centrifugation at 1900 × g for 10 min
at 4°C, the cell debris was removed. The remaining virus par-
ticles were then concentrated by centrifugation at 118;000 × g
for 1 h at 4°C through a 20% sucrose cushion in phosphate buf-
fered saline (PBS). The virus was stored in aliquots at −80°C.
The titer of the virus was measured by the tissue culture infec-
tious dose-50 (TCID50) assay.
17 For the TCID50 assay, MDCK
cells were plated on a 96-well plate. The virus was added in
10-fold dilutions using infection media (DMEM with 4 μg∕mL
N-acetylated trypsin and 0.03% BSA) for each successive
row of wells. The plates were stored in an incubator at 37°C
and 5% CO2. After 4 days, formaldehyde was added to fix the
cells and naphthol blue–black was added to stain the fixed cells.
The plates were washed and then the 50% infectious dose was
calculated using the Reed–Muench method.18
2.4 Laser Irradiation
The excitation laser source employed in this work was a diode-
pumped mode-locked Ti-sapphire laser. The laser produced
a continuous train of 65 fs pulses at a repetition rate of
80 MHz.14,15,19 The output of the second-harmonic generation of
the Ti-sapphire laser was used to irradiate the sample. The exci-
tation laser was chosen to operate at a wavelength of 415 nm and
with an average power of 140 mW. It had a pulse width of full
width at half maximum of about 100 fs. An achromatic lens of
focus length 7.5 cm was used to focus the laser beam into the
sample area. In order to facilitate the interaction of the laser with
the influenza virus particles, which were placed inside a Pyrex
cuvette with buffer solution, a magnetic stirrer was set up so
that virions would enter the laser-focused volume. All the laser-
irradiated influenza samples contained approximately 2 × 108
TCID50∕ml virus and had a volume of about 200 μl. The typical
exposure time of the sample to laser irradiation was about 8 h.
The diameter of the laser beam was approximately 100 μm
within the cuvette and the effective laser exposure time for indi-
vidual virions was estimated to be about 28 s. The sterility of
influenza virus samples after laser treatment was confirmed by
TCID50 assay. All the experimental results reported here were
obtained at 23°C and with a single laser beam excitation. The
temperature increase of sample solutions during USP laser
treatments, as monitored by a thermocouple, did not exceed
2°C. The inactivated virus was stored in aliquots at −80°C for
use in subsequent vaccination experiments.
2.5 Hemagglutination Assay
Live and the USP laser-inactivated virus preparations were seri-
ally twofold-diluted in a 100 ml volume on a 96-well microtitre
plate. A 0.5% chicken erythrocyte suspension was added to
all wells and plates were incubated for 30 min on ice. This
hemagglutination assay was adapted from current protocols in
microbiology.20
2.6 Immunization and Challenge
Groups of mice were vaccinated twice at a 2-week interval, as
previously described,21,22 with 2 × 108∕mL TCID50 (20 μl) of
laser-inactivated H1N1 virus by intranasal administration.
Control mice did not receive vaccine. The mice in both groups
maintained a consistent weight prior to administration of the
challenge dose. Two weeks after the last vaccination, the mice
were challenged with a lethal dose (6 × 102 TCID50) of H1N1,
and the weight of the mice was daily monitored. Mice losing
more than 25% of their body weight were considered to have
reached the experimental endpoint and were euthanized.
2.7 Flow Cytometry
Two weeks after the last vaccination, mice were sacrificed and
their splenocytes were isolated and stimulated using influenza
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nucleoprotein peptide (NP). Detection of cellular surface CD8a
and intracellular IFN-γ was performed using flow cytometry as
previously described.23 Briefly, the cells were incubated for
overnight with 1 μg∕ml of GolgiPlug (BD Pharmingen) in
the presence of 2 μg∕ml of NP peptide. After washing with
FACScan buffer, the cells were stained with phycoerythrin-con-
jugated anti-mouse CD8a antibody. The cells were then incu-
bated with BD cytofix/cytoperm solution (BD Pharmingen)
followed by staining with FITC-conjugated anti-mouse IFN-γ
antibody. The splenocytes of all the mice in each group were
pooled together and then analyzed by flow cytometry on a
Becton-Dickinson FACSCalibur with CellQuest software (BD
Biosciences, Mountain View, California). Gating was performed
on the lymphocyte area.
2.8 Microneutralization Assay
Blood was collected from the tail vein of vaccinated (n ¼ 5) or
unvaccinated (n ¼ 4) mice 2 weeks after the last vaccination.
The serum was stored in aliquots at 4°C. After the serum
was collected, the mice were tested for H1N1-specific neutral-
izing antibodies as follows. 2 × 104 MDCK cells were plated in
each well of a 96-well plate. Serum was diluted with infection
media (DMEM with 4 μg∕mL N-acetylated trypsin and 0.03%
BSA) to 1:100 and added to the first row of wells containing the
MDCK cells. After thorough mixing of the well contents, 25 μl
of the first row’s wells were added to 25 μl of infection media in
the next row. This procedure was continued until the last row of
wells, resulting in two-fold dilutions, then the extra serum was
discarded. A constant H1N1 concentration of 1.75 × 105
TCID50∕well was used for each plate. The virus and serum were
incubated at 25°C for 2 hours and then added to the 96-well plate
with MDCK cells. The plates were stored for three nights in an
incubator at 37°C and 5% CO2. Formaldehyde and naphthol
blue–black was added to visualize the results of the reaction as
in the TCID50 assay. This assay was repeated three times.
Neutralization titers were calculated using the Reed–Muench
method. The inverse of the highest dilution at which 50% pro-
tection was achieved was determined to be the neutralization
titer of the serum.24
2.9 ELISA
The levels of anti-influenza antibodies in sera were determined
by a direct enzyme-linked immunosorbent assay (ELISA) as
previously described.25,26 Briefly, wells of a 96-microwell
plate were coated with 100 μl of a 4 μg∕ml of influenza and
incubated at 4°C overnight. The wells were then blocked with
PBS containing 20% fetal bovine serum. Sera were prepared
from the mice on day 14 postimmunization, 100 times diluted
in PBS, added to the ELISAwells, and incubated at 37°C for 2 h.
After being washed with PBS containing 0.05% Tween 20, the
plate was incubated with a 1/2,000 dilution of a peroxidase-con-
jugated rabbit anti-mouse immunoglobulin G antibody (Zymed,
San Francisco, California) at room temperature for 1 h. The plate
was washed six times, and then 1-Step Turbo TMB-ELISAwas
used as a substrate for color development (Pierce, Rockford,
Illinois); color development was stopped with 1 M H2SO4.
The absorbance of the ELISA plate wells was then determined
with a standard ELISA reader at 450 nm.
2.10 Protein Carbonyl Quantification
The carbonyl concentrations in untreated BSA, USP laser-
treated BSA, or UV-treated BSAwere assessed using a dinitro-
phenylhydrazine (DNPH)-based protein carbonyl colorimetric
assay kit (Cayman Chemical) according to the manufacturer’s
instructions. In the UV treatment group, BSA samples were
exposed to a Phillips TUV30W 30-Watt germicidal UVC lamp
at a 4-cm distance from the bulb for 90 min.
2.11 Statistical Analysis
Data were analyzed using Microsoft Excel 2010. Each experi-
ment was repeated in duplicate or triplicate. Individual data
points were compared using Student’s t test.
3 Experimental Results
3.1 Effect of the Ultrashort Pulsed Laser Virus
Inactivation on Hemagglutination Activity
Hemagglutination activity after the USP laser virus inactivation
provides one indicator to the structural alternation of the surface
proteins of the virus inactivation treatment. Purified influenza
stock was aliquoted into batches and treated with the USP
laser irradiation. Following the complete loss of infectivity, we
compared the hemagglutination activity of live and inactivated
viruses. As shown in Table 1, within the experimental uncer-
tainty, hemagglutination activity was not affected by the USP
laser irradiation. These results provide evidence that the USP
laser irradiation, among other inactivation methods, causes the
least structural changes to viral surface proteins.
3.2 Laser-Inactivated H1N1 Influenza Vaccine
Confers Protection against Lethal H1N1
Challenge in Mice
We determined whether the laser-inactivated H1N1 virus vac-
cine conferred protection against a lethal dose of H1N1. The
percent of change from initial weight was used as an indicator
of the health of the mice. Groups of mice received vaccination
(n ¼ 8) or no treatment (n ¼ 8). Two weeks after the last vac-
cination, mice in both groups were given a lethal dose of 6 × 102
TCID50∕mL live H1N1 virus. Following administration of the
challenge dose, the weights of mice in the control group rapidly
decreased. As shown in Fig. 1, by the seventh day after receiving
the challenge dose, control mice lost a significant percentage of
their initial weight, while the mice in the vaccinated group main-
tained healthy weights. Our results show that vaccination is
87.5% effective against a challenge of lethal dose.
Table 1 Hemagglutination activity of live and the ultrashort pulsed
(USP) laser-inactivated influenza virus with A/PR/8/34 strain.
Strain Method of inactivation HAU/ml
A/PR/8/34
Original live stock ð2.3 0.2Þ × 105
USP laser inactivation ð2.1 0.2Þ × 105
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3.3 Laser-Inactivated H1N1 Influenza Vaccine
Increases CD8þ Immune Response in Mice
To further investigate the immunity generated by vaccination
with laser-inactivated virus, CTL activation was assessed.
Splenocytes were obtained from vaccinated or untreated mice
and stimulated by immunogenic influenza NP peptide. Cells
were fluorescently tagged for CD8 and IFN-γ and analyzed by
flow cytometry. Figure 2 demonstrates that the vaccinated mice
show a 10-fold increase in the percentage of activated NP
peptide-specific T cells in comparison to the control mice.
These data indicate that vaccination with laser-inactivated virus
generates influenza antigen-specific CD8þ T cell immune
responses.
3.4 Laser-Inactivated H1N1 Influenza Vaccine
Generates Influenza-Specific Neutralizing
Antibodies
We next investigated humoral immunity induced by vaccination
using a microneutralization assay. This neutralization assay is a
sensitive and specific technique to measure neutralizing anti-
body responses to H1N1 virus. As shown in Fig. 3, we found
that sera from mice that received laser-inactivated vaccination
showed a significantly higher neutralizing antibody titer com-
pared to sera from control (unvaccinated) mice. Furthermore,
we observed that vaccination with decreasing doses of laser-
inactivated influenza virus generated virus-specific antibody
responses to lesser degrees. These experimental results indicate
that vaccination with laser-inactivated virus induces neutralizing
antibody immune responses.
3.5 Transmission Electron Microscopy Images
Reveal that the Laser-Inactivated Virus Retains
Its Global Viral Structure
We used transmission electron microscopy (TEM) to visually
examine the active and laser-inactivated influenza viruses.
Figures 4(a) and 4(b) show the TEM images of the influenza
virus with or without laser irradiation, respectively. We have
found that the global structure of the virus is maintained after
the USP laser treatment, indicative of the production of WIV
by the USP laser irradiation.
3.6 Laser Treatment Does Not Generate Carbonyl
Groups in Protein
Conventional inactivation methods including formalin, UV
treatment, and gamma radiation are potent inducers of carbonyl
Fig. 1 Body weight changes in H1N1-challenged mice. Groups of
BALB/c mice (n ¼ 8) were vaccinated twice with 2 × 108 TCID50∕ml
(20 μl) of laser-inactivated H1N1 virus by intranasal administration at
a 2-week interval, or received no treatment. 21 days later, all mice
were challenged with a lethal dose of 6 × 102 TCID50∕mL of A/PR/
8/34 influenza virus. Following lethal challenge, mice were monitored
for percent change of initial weight for 9 days. Each point represents
the mean and bars represent standard deviation. (Student’s t test
comparing the final weights of each group of mice, P ¼ 0.026).
Fig. 2 CD8þ T cell induction following vaccination. Splenocytes were isolated from vaccinated and
untreated BALB/c mice and then the cells were incubated overnight in the presence of 2 μg∕ml of
NP peptide. After washing with FACScan buffer, the cells were stained with phycoerythrin-conjugated
anti-mouse CD8a antibody, followed by fixing/permeabilizing and staining with FITC-conjugated anti-
mouse IFN-γ antibody. The splenocytes were then analyzed by flow cytometry on a FACSCalibur
with CellQuest software, and gated on the lymphocyte area. (a) Representative flow cytometry analysis.
The upper right-hand quadrant shows the percentage of NP-specific, IFN-γ secreting CD8þ T cells
among lymphocytes. (b) Bar graph depicting the percentage of activated CD8þ T cells among spleno-
cytes in vaccinated and unvaccinated mice (P < 0.001).
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groups in protein;4,10,11,27 these carbonyl groups are in turn
inducers of harmful and undesirable T helper type 2
responses.4,5 To determine whether laser treatment generates
protein carbonylation, we used a colorimetric 2,4-dinitrophenyl-
hydrazine (DNPH)-based assay to quantitate carbonyl content in
laser-treated BSA. Untreated BSA or UV-treated BSA served as
negative and positive controls, respectively. Figure 5 shows that
there is no significant increase in carbonyl content in laser-
treated BSA samples relative to untreated BSA. In contrast, the
carbonyl content of the UV-treated BSA was dramatically
increased relative to both untreated and laser-treated BSAs
(p ¼ 0.0004). These results demonstrate that USP laser treat-
ment generates fewer carbonyl groups in protein antigens
compared with conventional pathogen inactivation methods,
reducing the risk of detrimental vaccine-elicited Th2 responses.
4 Discussion
Because of the following two reasons, the complete inactivation
of H1N1 flu viruses in the sample by the USP laser irradiation
observed in our experiments and used for the vaccine cannot be
due to the two-photon absorption effect. First, we have esti-
mated the number of UVC photons which might be produced at
the laser power densities used in our experiments. The two-pho-
ton absorption coefficient for H1N1 flu virus is not available in
the literature; however, if we assume that the viruses are giant
molecules and that their two-photon absorption coefficient at
415 nm is comparable to that of a typical molecule,28 then
the number of UVC photons at 208 nm generated under our
experimental conditions was estimated to be of the order of
0.1/ second. Because the laser exposure time is 8 h, the number
of generated UVC photons is about 3000 for the total laser expo-
sure time. On the other hand, the total number of H1N1 viral
particles in the laser-irradiated sample is about 200 million;
since one UVC photon at 208 nm can inactivate only one viral
particle, the value of generated UVC photons of about 3000 dur-
ing the total laser exposure time is too small to account for the
complete inactivation of 200 million viral particles observed in
our experiments. Second, we have tried to detect the UVC pho-
tons which might be generated in our laser experiments (here,
the glass vial is replaced by a synthetic fused silica vial) by using
a UV spectrometer with a photon counting system. Within our
experimental uncertainty of 0.5 photon∕second, we failed to
detect any of the UVC photons at 208 nm. This finding is con-
sistent with our estimation stated above. In addition, we note
that the absorption coefficient of water at 208 nm is about
0.05 cm−1, which means that the effect of water absorption at
208 nm is negligible and cannot be the reason for not detecting
the UVC photon. Therefore, the observed complete inactivation
for H1N1 flu virus observed in our experiments cannot be due to
UVC photons generated by two-photon absorption.
It has been shown that nonenveloped viruses such as murine
norovirus (MNV) are inactivated by a visible USP laser through
the ISRS process,16 whereby the USP laser pulses excite Raman-
active vibrational modes on the capsid of the nonenveloped
Fig. 3 Neutralizing antibodies detected by microneutralization assay.
Serum from vaccinated (n ¼ 5) and unvaccinated (n ¼ 4) groups of
mice was extracted 20 days after vaccination and then added to
Madin-Darby canine kidney (MDCK) cells in a 96-well plate, serially
diluted, and incubated for 3 days. Subsequently, a constant H1N1
concentration of 1.75 × 105 TCID50∕well was used for each plate.
The virus and serum were incubated at 25°C for 2 h and then
added to the 96-well plate with MDCK cells. The plates were stored
for three nights in an incubator at 37°C and 5% CO2. Formaldehyde
and naphthol blue–black was added to visualize the results of the
reaction. The presence of neutralizing antibodies was determined
by cell survival. Neutralization titers were calculated using the Reed–
Muench method. Bar graph depicts neutralization titer of untreated
and vaccinated mice. (P ¼ 0.021).
Fig. 4 Transmission electron microscopy (TEM) images of influenza
virus. Samples of laser-inactivated and active A/PR/8/34 influenza
virus were fixed with glutaraldehyde and visualized using TEM.
(a) Fixed sample of laser-inactivated virus at 93;000× magnification.
(b) Fixed sample of the active virus at 93;000× magnification. These
TEM images demonstrate the retention of capsid and global structure
of the influenza virus after the ultrashort pulsed (USP) laser irradiation
and provide support for the laser-induced protein aggregation through
ISRS process for the most likely inactivation mechanism.
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virus––MNV. The amplitude of the vibration is linearly propor-
tional to the laser intensity. When the laser intensity is suffi-
ciently large, the excited amplitude of vibration on the capsid
can become extremely large, leading to the breaking of weak
links such as hydrogen bonds and hydrophobic contacts in
the capsid of the virus. This causes the capsid to disintegrate
into subunits. The virus becomes inactivated because of the
loss of integrity of its capsid. On the other hand, it has been
demonstrated that enveloped viruses such as murine cytomega-
lovirus (MCMV) are inactivated by a visible USP laser via the
ISRS process as well but through a different route/pathway.19
The USP laser pulses excite Raman-active modes on the pro-
teins of the capsid as well as the tegument proteins of the envel-
oped virus––MCMV through the impulsive stimulated Raman
scattering process. The excitations, which break the hydrogen
bonds and hydrophobic contacts on these proteins, cause partial
unfolding of the proteins. These unfolded proteins will rapidly
reform their broken weak hydrogen bonds and hydrophobic
contacts and return to their original folded configuration.
However, if the concentration of proteins is very high, such
as in the case of proteins confined within the capsid of a
virus, they can form hydrogen bonds and hydrophobic contacts
with other proteins nearby, leading to the aggregation of pro-
teins. This has been the case for the enveloped virus––
MCMV. Aggregation between capsid proteins and tegument
proteins has been found to be the cause of inactivation for an
enveloped virus. All influenza viruses are enveloped viruses.
Therefore, we believe that the most likely inactivation mecha-
nism for the H1NI influenza virus inactivated by the visible USP
laser studied here is the ISRS process. The TEM images of
H1N1 influenza virus before and after the USP laser irradiation,
shown in Fig. 4, further support our argument. The striking
similarity between these TEM images to those of MCMV,19
i.e., the retention of the capsid and the global structure of the
virus, suggests that the effects (and, therefore, the underlining
inactivation mechanism) of the USP laser irradiation on these
two enveloped viruses are the same.
To give a perspective on the vaccine potency reported in our
current study, it is illustrative to compare the vaccine dosages
required for protection against lethal challenge in mice using
conventional or laser-inactivated H1N1 influenza vaccines.
Among conventional methods including heat, formalin, beta
propiolactone, and detergents, formalin was found to have the
greatest preservation of influenza vaccine antigens.13 We have
performed additional experiments in which two control groups
of mice got conventional formalin-inactivated H1N1 influenza
vaccine. Figure 6(a) shows one control group vaccinated with
two doses of conventional formalin-inactivated H1N1 vaccine at
≈2.76 × 106 pfu∕dose, which was the dose of the USP laser-
inactivated vaccine that we used for protection against the chal-
lenge. Figure 6(b) shows the other control group vaccinated with
two doses of conventional formalin-inactivated H1N1 vaccine at
Fig. 5 Carbonyl content of laser-treated bovine serum albumin
(BSA) protein. The carbonyl concentrations in untreated BSA, USP
laser-treated BSA, or UV-treated BSA were assessed using a dinitro-
phenylhydrazine (DNPH) protein carbonyl colorimetric assay kit.
Untreated BSA served as negative control; UV-treated BSA served
as positive control.
Fig. 6 Body weight changes in H1N1-challenged mice vaccinated
with conventional formalin-inactivated vaccine. (a) One control group
vaccinated with two doses of conventional formalin-inactivated
H1N1 vaccine at ≈2.76 × 106 pfu∕dose; (b) the other control group
vaccinated with two doses of conventional formalin-inactivated
H1N1 vaccine at ≈2.76 × 107 pfu∕dose. The mice of the control
group in (a) all died (the weights decreased more than 30% of their
initial ones) 10 days after challenging; whereas the mice of the control
group in (b) achieved 75% protection.
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≈2.76 × 107 pfu∕dose. The mice of the control group in
Fig. 6(a) all died (the weights decreased more than 30% of
their initial ones) 10 days after challenging; whereas the mice
of the control group in Fig. 6(b) achieved 75% protection.
On the other hand, with the visible USP laser irradiation method,
we employed two doses of USP laser-inactivated vaccine at
≈2.76 × 106 pfu∕dose, which is a 10-fold lower dose relative
to the formalin-inactivated vaccine, to achieve 87.5% protection.
Therefore, these results indicate that the USP laser-inactivated
vaccine is significantly more efficient than the vaccine prepared
by the conventional formalin-inactivated vaccine.
The relatively high potency of the USP laser-inactivated
influenza virus vaccine can be partly attributed to the fact that
the visible USP laser irradiation has minimal effects on the struc-
ture of proteins. The circular dichroism (CD) spectrum of BSA
protein measured before and after the USP laser irradiation is a
good example. The CD spectrum is very sensitive to the secon-
dary structure of proteins. It has been shown that, within exper-
imental uncertainty, there is no change in the CD spectrum of
BSA protein before and after USP laser irradiation.15 These
spectroscopic results are in line with our hemagglutination activ-
ity results. Our experimental results on the hemagglutination
activity of the virus show that, within the experimental uncer-
tainty, the USP laser irradiation has no effects on the surface
protein structure of the virus.
We note that the USP laser-inactivated influenza vaccine may
generate heterosubtypic immunity, which is the aim of current
efforts to design universal influenza vaccines. The CTL
response is a key mechanism for improved heterosubtypic pro-
tection against influenza because CTLs have been shown to be
specific for epitopes that are conserved among viral subtypes.29
Our data showed that splenocytes from vaccinated mice showed
a 10-fold increase of influenza NP-specific CTLs compared to
unvaccinated mice. These results suggest that the laser-inacti-
vated influenza vaccine has the potential to generate cross-pro-
tection against multiple strains and address the issue of viral
mutation.
The presence of carbonyl groups in vaccine antigens has
been linked to the induction of undesirable and potentially del-
eterious Th2-mediated immunopathology.4,5 Many inactivation
techniques including UVand gamma radiation are potent induc-
ers of protein carbonylation.4,10,11,27 We note that although form-
aldehyde is not an oxidizing agent and cannot produce oxidative
damage in a cell free system, the carbonyl groups introduced
into proteins by formaldehyde in the formalin inactivation tech-
nique have something in common with the carbonyl groups
introduced by protein oxidation.
In contrast to these techniques, visible USP lasers lack the
energy to disrupt covalent structures in proteins. Therefore, we
reasoned that USP laser treatment would not cause protein car-
bonylation. The experimental results in Fig. 5 confirm this.
These data demonstrate that USP laser treatment does not gen-
erate significant levels of carbonyl groups in protein antigens
compared with conventional pathogen inactivation methods,
reducing the risk of detrimental vaccine-elicited Th2 responses.
In addition to carbonyl groups, other types of covalent damage
caused by formalin, UV, and gamma radiation can result in the
formation of “neoantigens” and elicit adverse immune reactions
when administered to patients, as was seen in penicillin aller-
gies30 and certain chemically treated blood products.31 In
contrast, the USP laser inactivates enveloped influenza virus
through the disruption of weak, noncovalent hydrogen bonds
and hydrophobic contacts in the virion, leading to the aggrega-
tion of capsid and tegument proteins. As a result, there is an
overall reduced concern of side effects from vaccines prepared
by the USP laser treatment method.
5 Conclusion
In summary, we have demonstrated a novel USP laser irradiation
method for the production of safe and potent WIV vaccines. We
envision that the future of pathogen inactivation technologies
will favor chemical-free methods that target properties specific
to pathogens while preserving desirable components of the
treated product, leading to improved safety profiles. The USP
laser irradiation method we have presented in this report is one
such potential technology. Further, evaluation of the USP laser-
inactivated vaccine for cross-protection and in the context of
other important pathogens such as HIV, SARS, and MERS is
warranted.
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